Nonalcoholic fatty liver (NAFLD)
Conditions
Interventions
NMN intervention group:Supplement 1000mg NMN daily
Placebo group:Supplement 1000mg of placebo daily
Sponsors
Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. 18-65 year old patients with non-alcoholic fatty liver disease; regardless of gender; 2. According to the diagnosis and treatment guidelines of non-alcoholic fatty liver disease, it meets the diagnostic criteria of non-alcoholic simple fatty liver disease 3. Sign the informed consent 4. Regular meals, stable weight in the past three months, no heavy drinking or overeating in the past two weeks.
Exclusion criteria
Exclusion criteria: 1. long-term use of drugs that are known to cause hepatic steatosis or steatohepatitis; 2. There is a history of heavy drinking or alcohol consumption cannot be quantified (The alcohol consumption was more than 140 g/week for men and 70 g/week for women); 3. Liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis; 4. Have cardiovascular disease, severe liver and kidney disease, or other systemic diseases; 5. Patients with a history of major illness or recent major trauma, surgery, or infection; 6. Patients who are not suitable to participate in the disease study of this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver fat content;Nicotinamide Adenine Dinucleotide;Alanine aminotransferase;Aspartate aminotransferase; | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI;Waist circumference;Hip circumference;Gamma-glutamyltransferase;Alkaline phosphatase;Triglyceride;Low density lipoprotein cholesterol;High density lipoprotein cholesterol;N-methyl-2-pyridone-5-carboxamide;Direct Bilirubin;Indirect Bilirubin;Serum total protein;Serum albumin;Serum globulin;Albumin/globulin ratio;Cholinesterase; | — |
Countries
China
Contacts
Public ContactSongtao Li
Zhejiang Chinese Medical University
Outcome results
None listed